SCHEMBL6183402

SCHEMBL6183402

CC(C)Cc1cc(-c2ccc(Cn3c(-c4ccccc4)nc(Cl)c3C=O)cc2)c(NS(=O)(=O)C(C)(C)C)s1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAS1 P04201 1/20 0.54
▸ AGTR2 P50052 8/20 0.37
▸ GP6 Q9HCN6 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ GMNN O75496 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ TP53 P04637 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ NFKB1 P19838 1/20 0.34
▸ APEX1 P27695 1/20 0.34
▸ AGTR1 P30556 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ THPO P40225 1/20 0.34
▸ MTOR P42345 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6183698 0.91 MAS1 (0.45) MAS1AGTR2
SCHEMBL6185055 0.90 MAS1 (0.46) MAS1AGTR2GP6AGTR1
SCHEMBL7383678 0.88 MAS1 (0.55) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL3902365 0.83 MAS1 (0.55) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL3908044 0.79 MAS1 (0.69) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL3906331 0.78 MAS1 (0.68) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL3915251 0.78 MAS1 (0.69) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL7382680 0.78 MAS1 (0.47) MAS1AGTR2AGTR1
SCHEMBL1334134 0.77 MAS1 (0.74) MAS1AGTR2MEN1GMNNUSP2
SCHEMBL3975878 0.77 MAS1 (0.73) MAS1AGTR2MEN1GMNNUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1185527-B1 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS AVENTIS PHARMA GMBH (DE) 2005-07-27 — — EP disclosed
US-6429222-B2 HYPOTENSIVE AGENT, ENDOTHELIAL DAMAGE, ARTERIOSCLEROSIS, ANTIDIABETIC AGENTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-08-06 — — US disclosed
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-06-20 — — US disclosed
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2001-08-30 — — US disclosed
US-6235766-B1 HYPOTENSIVE AGENTS; CARDIOVASCULAR DISORDERS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2001-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010018449-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical preparations comprising them AGTR1, NPR1, EDNRB MAS1 362/4885AGTR2 7/4885GP6 433/4885
US-20020077344-A1 1-(p-thienylbenzyl)imidazoles as agonists of angiotensin (1-7) receptors, processes for their preparation, their use, and pharmaceutical prepartions comprising them AGTR1, NPR1, EDNRB MAS1 427/4885AGTR2 8/4885GP6 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback